Literature DB >> 8579798

Detection of psychoactive drugs using 19F MR spectroscopy.

M Bartels1, K Albert.   

Abstract

In vivo 19F resonance spectroscopy measurements of trifluorinated neuroleptics (fluphenazine and trifluoperazine) and later trifluorinated antidepressants (fluoxetine and fluvoxamine) began with animal experiments in 1983. Using rats which have been treated with high oral doses of fluphenazine over a period of three weeks in the beginning of these experiments the measurement time was very long (up to 10 h). The application of better techniques using surface coils led to marked improvement of the signal noise ratio and measurement times in animal experiments could be reduced to minutes. These results encouraged us and other groups to perform experiments in humans to detect and try to estimate brain levels of trifluorinated neuroleptics and antidepressants. The present data of several research groups demonstrate that 19F MR spectroscopy has the potential of becoming a valuable tool for monitoring drug levels at the site of action. The extension of the animal studies to humans might facilitate a better treatment of schizophrenic and depressive patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8579798     DOI: 10.1007/bf01271467

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  10 in total

1.  Detection of psychoactive drugs in vivo in humans using 19F NMR spectroscopy.

Authors:  R A Komoroski; J E Newton; C Karson; D Cardwell; J Sprigg
Journal:  Biol Psychiatry       Date:  1991-04-01       Impact factor: 13.382

2.  Noninvasive in vivo detection of a fluorinated neuroleptic in the human brain by 19F nuclear magnetic resonance spectroscopy.

Authors:  P Durst; N Schuff; M A Crocq; M C Mokrani; J P Macher
Journal:  Psychiatry Res       Date:  1990-12       Impact factor: 3.222

3.  Fluorinated psychopharmacological agents: noninvasive observation by fluorine-19 nuclear magnetic resonance.

Authors:  M Bartels; K Albert; G Kruppa; K Mann; G Schroth; S Tabarelli; M Zabel
Journal:  Psychiatry Res       Date:  1986-07       Impact factor: 3.222

4.  Blood to brain distribution of neuroleptics.

Authors:  T Sunderland; B M Cohen
Journal:  Psychiatry Res       Date:  1987-04       Impact factor: 3.222

5.  In vivo 19F nuclear magnetic resonance of a monofluorinated neuroleptic in the rat.

Authors:  U Günther; K Albert
Journal:  NMR Biomed       Date:  1993 Jan-Feb       Impact factor: 4.044

6.  In vivo 19F nuclear magnetic resonance spectroscopy of trifluorinated neuroleptics in the rat.

Authors:  K Albert; H Rembold; G Kruppa; E Bayer; M Bartels; G Schmalzing
Journal:  NMR Biomed       Date:  1990-06       Impact factor: 4.044

7.  Human brain fluoxetine concentrations.

Authors:  C N Karson; J E Newton; R Livingston; J B Jolly; T B Cooper; J Sprigg; R A Komoroski
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1993       Impact factor: 2.198

8.  19F nuclear magnetic resonance spectroscopy of neuroleptics: the first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain.

Authors:  M Bartels; U Günther; K Albert; K Mann; N Schuff; H Stuckstedte
Journal:  Biol Psychiatry       Date:  1991-10-01       Impact factor: 13.382

9.  Reduced haloperidol in the post-mortem brains of haloperidol-treated patients.

Authors:  E R Korpi; J E Kleinman; D T Costakos; M Linnoila; R J Wyatt
Journal:  Psychiatry Res       Date:  1984-03       Impact factor: 3.222

10.  In vivo 19F spin relaxation and localized spectroscopy of fluoxetine in human brain.

Authors:  R A Komoroski; J E Newton; D Cardwell; J Sprigg; J Pearce; C N Karson
Journal:  Magn Reson Med       Date:  1994-02       Impact factor: 4.668

  10 in total
  2 in total

Review 1.  New frontiers and developing applications in 19F NMR.

Authors:  Jian-Xin Yu; Rami R Hallac; Srinivas Chiguru; Ralph P Mason
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2012-11-02       Impact factor: 9.795

Review 2.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.